Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed...

ENHERTU now available in Japan as first ADC for the second-line treatment of patients with...

ENHERTU approved in Japan as first tumor agnostic HER2 directed medicine for previously treated patients...

GSK’s B7-H3-targeted ADC, Risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan

Tempus announces strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation...

GlycoNex Inc. and Nippon Kayaku Co., Ltd. enter collaboration to advance next-generation ADC candidate GNX201-ADC